Skip to main content
. 2024 Jun 28;119(12):2398–2407. doi: 10.14309/ajg.0000000000002924

Figure 3.

Figure 3.

Change from baseline in EoE-IQ average score at weeks 12 and 24 (a), and individual item scores at week 24 (b). *Nominal P ≤ 0.05, **nominal P ≤ 0.01, ***nominal P ≤ 0.001, ****nominal P ≤ 0.0001 dupilumab vs placebo. EoE-IQ, eosinophilic esophagitis Impact Questionnaire; LS, least squares; qw, once weekly.